Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Antiapoptotic
23%
Forodesine
18%
Hydrogen Peroxide
16%
Malignant Neoplasm
14%
Caspase 3
13%
Fludarabine
12%
Cyclophosphamide
12%
Clinical Trial
11%
Venetoclax
10%
Bendamustine
10%
Duvelisib
10%
Pharmacodynamics
9%
Bruton Tyrosine Kinase Inhibitor
9%
Acute Lymphoblastic Leukemia
9%
Drug Resistance
9%
Leukemia
9%
Protein Kinase
9%
Ibrutinib
9%
Clofarabine
9%
Acalabrutinib
9%
Diseases
8%
Reactive Oxygen Metabolite
8%
Adenosine Triphosphate
7%
B Lymphocyte Receptor
7%
Protein Mcl 1
7%
Cytotoxicity
6%
Gossypol
6%
Purine Nucleoside Phosphorylase
6%
Deoxyguanosine Triphosphate
5%
Combination Therapy
5%
B Cell Lymphoma
5%
Adenosine
5%
Hematologic Malignancy
5%
Deoxyguanosine
5%
Keyphrases
Chronic Lymphocytic Leukemia
48%
Chronic Lymphocytic Leukemia Cells
27%
Apoptosis
13%
Myeloid Cell leukemia-1 (Mcl-1)
12%
Anti-apoptotic Proteins
10%
Mantle Cell Lymphoma
10%
Bone Marrow
10%
Stromal Microenvironment
10%
Duvelisib
10%
Bendamustine
9%
Venetoclax
9%
Forodesine
9%
Fludarabine
9%
Bcl-2 Family
8%
Caspase-3
7%
Gossypol
7%
Relapsed or Refractory
6%
RNA Synthesis
6%
Leukemia Lymphocytes
5%
Cyclophosphamide
5%
BH3 Mimetics
5%
B-cell Lymphoma
5%
Therapeutic Target
5%
Primary Cells
5%
Protein Kinase
5%
B-cell Receptor Signaling
5%
Phase II Trial
5%
DNA Damage Response
5%
ABT-199
5%
Smac
5%
Biochemistry, Genetics and Molecular Biology
Programmed Cell Death
24%
Stromal Cell
21%
B Cell
17%
Bcl-2 Family
9%
Crosslinking of DNA
9%
Hydrogen Peroxide
9%
B-Cell Receptor
9%
Cancer Cell
9%
Lymphocyte
8%
Cell Survival
7%
Deoxyguanosine Triphosphate
7%
Clinical Trial
6%
Purine Nucleoside Phosphorylase
6%
Phosphotransferase
6%
Kinase
6%
Oxidative Phosphorylation
6%
Fludarabine
6%
Oxygen Consumption
5%
Primary Cell
5%
Anticancer
5%
DNA Synthesis
5%
Caspase 3
5%
Deoxyguanosine
5%
X-Linked Inhibitory Apoptosis Protein
5%
Drug Resistance
5%
Transcription
5%
